RECENT HIV REPORTS on NATAP WEBSITE
http://www.natap.org
Herpes Zoster in Women With and at Risk for HIV: Data From the Women's Interagency HIV Study - (09/30/05)
Protease Inhibitors Adversely Affect Coronary Artery Function - (09/29/05)
Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance - (09/29/05)
High rate of virological failure with didanosine and tenofovir in treatment-experienced patients - (09/29/05)
Response to hepatitis A vaccine in HIV patients in the HAART era: CD4 count at time of vaccination determines response to vaccine - (09/29/05)
Protease inhibitors and NNRTIs have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens - (09/29/05)
DRUG-DRUG INTERACTIONS BETWEEN HAART, MEDICATIONS USED IN SUBSTANCE USE TREATMENT, AND RECREATIONAL DRUGS - (09/27/05)
Low CD4 Count May Accelerate Liver-Associated Deaths, and Heart & Malignancy Associated Deaths: D.A.D Study - (09/27/05)
House Bill Pushes Study of Topical Microbicides as HIV Prevention for Women - (09/27/05)
Reyataz & Methadone: no drug interaction observed - (09/27/05)
DHHS Recommendations for Care of HIV+ Individuals Displaced by Hurricanes - (09/27/05)
HIV+ Should Register with FEMA Diaster Assistance - (09/27/05)
Interview with Beth Scalco, Louisiana AIDS Director - (09/27/05)
Insulin Resistance in HIV-Infected Men and Women in the Nutrition for Healthy Living Cohort - (09/27/05)
Fat Distribution in Men With HIV Infection (FRAM) - (09/27/05)
Presence of Neurocognitive Impairment Requires More Potent HAART & Special Considerations - (09/27/05)
Appointing New FDA Commissioner - (09/27/05)
New Supply Chain Set Up for HIV Medicine in Africa - (09/27/05)
Incyte Announces Outcome of Discussions with FDA Regarding Reverset - (09/27/05)
Safety and distribution of cellulose acetate 1,2-benzenedicarboxylate (CAP), a candidate anti-HIV microbicide in rhesus macaques - (09/26/05)